Global Prostate Cancer Nuclear Medicine Diagnostics Market 2021 by Company, Regions, Type and Application, Forecast to 2026

  • receipt Report ID : 207667
  • calendar_today Published On: Apr, 2021
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Prostate Cancer Nuclear Medicine Diagnostics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Prostate Cancer Nuclear Medicine Diagnostics size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Prostate Cancer Nuclear Medicine Diagnostics market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation

Prostate Cancer Nuclear Medicine Diagnostics market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

SPECT

PET

Market segment by Application, can be divided into

Hospitals

Clinics

Others

Market segment by players, this report covers

Blue Earth Diagnostics

PETNET Solutions

Cardinal Health

Lantheus Medical Imaging

Jubilant Pharma

NCM-USA

Progenics Pharma

Telix Pharma

ImaginAb

Theragnostics

Novartis

Alliance Medical

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Prostate Cancer Nuclear Medicine Diagnostics

1.2 Classification of Prostate Cancer Nuclear Medicine Diagnostics by Type

1.2.1 Overview: Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type: 2020 Versus 2021 Versus 2026

1.2.2 Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Type in 2020

1.2.3 SPECT

1.2.4 PET

1.3 Global Prostate Cancer Nuclear Medicine Diagnostics Market by Application

1.3.1 Overview: Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application: 2020 Versus 2021 Versus 2026

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Others

1.4 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size & Forecast

1.5 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast by Region

1.5.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region: 2016 VS 2021 VS 2026

1.5.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region, (2016-2021)

1.5.3 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size and Prospect (2016-2026)

1.5.4 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size and Prospect (2016-2026)

1.5.5 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size and Prospect (2016-2026)

1.5.6 South America Prostate Cancer Nuclear Medicine Diagnostics Market Size and Prospect (2016-2026)

1.5.7 Middle East and Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size and Prospect (2016-2026)

1.6 Market Drivers, Restraints and Trends

1.6.1 Prostate Cancer Nuclear Medicine Diagnostics Market Drivers

1.6.2 Prostate Cancer Nuclear Medicine Diagnostics Market Restraints

1.6.3 Prostate Cancer Nuclear Medicine Diagnostics Trends Analysis

2 Company Profiles

2.1 Blue Earth Diagnostics

2.1.1 Blue Earth Diagnostics Details

2.1.2 Blue Earth Diagnostics Major Business

2.1.3 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions

2.1.4 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019-2021)

2.1.5 Blue Earth Diagnostics Recent Developments and Future Plans

2.2 PETNET Solutions

2.2.1 PETNET Solutions Details

2.2.2 PETNET Solutions Major Business

2.2.3 PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions

2.2.4 PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019-2021)

2.2.5 PETNET Solutions Recent Developments and Future Plans

2.3 Cardinal Health

2.3.1 Cardinal Health Details

2.3.2 Cardinal Health Major Business

2.3.3 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions

2.3.4 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019-2021)

2.3.5 Cardinal Health Recent Developments and Future Plans

2.4 Lantheus Medical Imaging

2.4.1 Lantheus Medical Imaging Details

2.4.2 Lantheus Medical Imaging Major Business

2.4.3 Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions

2.4.4 Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019-2021)

2.4.5 Lantheus Medical Imaging Recent Developments and Future Plans

2.5 Jubilant Pharma

2.5.1 Jubilant Pharma Details

2.5.2 Jubilant Pharma Major Business

2.5.3 Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions

2.5.4 Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019-2021)

2.5.5 Jubilant Pharma Recent Developments and Future Plans

2.6 NCM-USA

2.6.1 NCM-USA Details

2.6.2 NCM-USA Major Business

2.6.3 NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions

2.6.4 NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019-2021)

2.6.5 NCM-USA Recent Developments and Future Plans

2.7 Progenics Pharma

2.7.1 Progenics Pharma Details

2.7.2 Progenics Pharma Major Business

2.7.3 Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions

2.7.4 Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019-2021)

2.7.5 Progenics Pharma Recent Developments and Future Plans

2.8 Telix Pharma

2.8.1 Telix Pharma Details

2.8.2 Telix Pharma Major Business

2.8.3 Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions

2.8.4 Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019-2021)

2.8.5 Telix Pharma Recent Developments and Future Plans

2.9 ImaginAb

2.9.1 ImaginAb Details

2.9.2 ImaginAb Major Business

2.9.3 ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions

2.9.4 ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019-2021)

2.9.5 ImaginAb Recent Developments and Future Plans

2.10 Theragnostics

2.10.1 Theragnostics Details

2.10.2 Theragnostics Major Business

2.10.3 Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions

2.10.4 Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019-2021)

2.10.5 Theragnostics Recent Developments and Future Plans

2.11 Novartis

2.11.1 Novartis Details

2.11.2 Novartis Major Business

2.11.3 Novartis Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions

2.11.4 Novartis Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019-2021)

2.11.5 Novartis Recent Developments and Future Plans

2.12 Alliance Medical

2.12.1 Alliance Medical Details

2.12.2 Alliance Medical Major Business

2.12.3 Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions

2.12.4 Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019-2021)

2.12.5 Alliance Medical Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Prostate Cancer Nuclear Medicine Diagnostics Revenue and Share by Players (2019-2021)

3.2 Market Concentration Rate

3.2.1 Top 3 Prostate Cancer Nuclear Medicine Diagnostics Players Market Share

3.2.2 Top 10 Prostate Cancer Nuclear Medicine Diagnostics Players Market Share

3.2.3 Market Competition Trend

3.3 Prostate Cancer Nuclear Medicine Diagnostics Players Head Office, Products and Services Provided

3.4 Mergers & Acquisitions

3.5 New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Prostate Cancer Nuclear Medicine Diagnostics Revenue and Market Share by Type (2016-2021)

4.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Forecast by Type (2021-2026)

5 Market Size Segment by Application

5.1 Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Application (2016-2021)

5.2 Prostate Cancer Nuclear Medicine Diagnostics Market Forecast by Application (2021-2026)

6 North America by Country, by Type, and by Application

6.1 North America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2016-2026)

6.2 North America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2016-2026)

6.3 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country

6.3.1 North America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2016-2026)

6.3.2 United States Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2016-2026)

6.3.3 Canada Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2016-2026)

6.3.4 Mexico Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2016-2026)

7 Europe by Country, by Type, and by Application

7.1 Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2016-2026)

7.2 Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2016-2026)

7.3 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country

7.3.1 Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2016-2026)

7.3.2 Germany Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2016-2026)

7.3.3 France Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2016-2026)

7.3.4 United Kingdom Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2016-2026)

7.3.5 Russia Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2016-2026)

7.3.6 Italy Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2016-2026)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2016-2026)

8.2 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2016-2026)

8.3 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region

8.3.1 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue by Region (2016-2026)

8.3.2 China Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2016-2026)

8.3.3 Japan Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2016-2026)

8.3.4 South Korea Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2016-2026)

8.3.5 India Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2016-2026)

8.3.6 Southeast Asia Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2016-2026)

8.3.7 Australia Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2016-2026)

9 South America by Country, by Type, and by Application

9.1 South America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2016-2026)

9.2 South America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2016-2026)

9.3 South America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country

9.3.1 South America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2016-2026)

9.3.2 Brazil Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2016-2026)

9.3.3 Argentina Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2016-2026)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2016-2026)

10.2 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2016-2026)

10.3 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country

10.3.1 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2016-2026)

10.3.2 Turkey Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2016-2026)

10.3.3 Saudi Arabia Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2016-2026)

10.3.4 UAE Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2016-2026)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026

Table 2. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026

Table 3. Global Market Prostate Cancer Nuclear Medicine Diagnostics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)

Table 4. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million) by Region (2016-2021)

Table 5. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Region (2021-2026)

Table 6. Blue Earth Diagnostics Corporate Information, Head Office, and Major Competitors

Table 7. Blue Earth Diagnostics Major Business

Table 8. Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions

Table 9. Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 10. PETNET Solutions Corporate Information, Head Office, and Major Competitors

Table 11. PETNET Solutions Major Business

Table 12. PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions

Table 13. PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 14. Cardinal Health Corporate Information, Head Office, and Major Competitors

Table 15. Cardinal Health Major Business

Table 16. Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions

Table 17. Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 18. Lantheus Medical Imaging Corporate Information, Head Office, and Major Competitors

Table 19. Lantheus Medical Imaging Major Business

Table 20. Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions

Table 21. Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 22. Jubilant Pharma Corporate Information, Head Office, and Major Competitors

Table 23. Jubilant Pharma Major Business

Table 24. Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions

Table 25. Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 26. NCM-USA Corporate Information, Head Office, and Major Competitors

Table 27. NCM-USA Major Business

Table 28. NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions

Table 29. NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 30. Progenics Pharma Corporate Information, Head Office, and Major Competitors

Table 31. Progenics Pharma Major Business

Table 32. Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions

Table 33. Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 34. Telix Pharma Corporate Information, Head Office, and Major Competitors

Table 35. Telix Pharma Major Business

Table 36. Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions

Table 37. Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 38. ImaginAb Corporate Information, Head Office, and Major Competitors

Table 39. ImaginAb Major Business

Table 40. ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions

Table 41. ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 42. Theragnostics Corporate Information, Head Office, and Major Competitors

Table 43. Theragnostics Major Business

Table 44. Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions

Table 45. Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 46. Novartis Corporate Information, Head Office, and Major Competitors

Table 47. Novartis Major Business

Table 48. Novartis Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions

Table 49. Novartis Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 50. Alliance Medical Corporate Information, Head Office, and Major Competitors

Table 51. Alliance Medical Major Business

Table 52. Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions

Table 53. Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 54. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million) by Players (2019-2021)

Table 55. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Share by Players (2019-2021)

Table 56. Breakdown of Prostate Cancer Nuclear Medicine Diagnostics by Company Type (Tier 1, Tier 2 and Tier 3)

Table 57. Prostate Cancer Nuclear Medicine Diagnostics Players Head Office, Products and Services Provided

Table 58. Prostate Cancer Nuclear Medicine Diagnostics Mergers & Acquisitions in the Past Five Years

Table 59. Prostate Cancer Nuclear Medicine Diagnostics New Entrants and Expansion Plans

Table 60. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million) by Type (2016-2021)

Table 61. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Share by Type (2016-2021)

Table 62. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Forecast by Type (2021-2026)

Table 63. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2016-2021)

Table 64. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Forecast by Application (2021-2026)

Table 65. North America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2016-2021) & (USD Million)

Table 66. North America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2021-2026) & (USD Million)

Table 67. North America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2016-2021) & (USD Million)

Table 68. North America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2021-2026) & (USD Million)

Table 69. North America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2016-2021) & (USD Million)

Table 70. North America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2021-2026) & (USD Million)

Table 71. Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2016-2021) & (USD Million)

Table 72. Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2021-2026) & (USD Million)

Table 73. Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2016-2021) & (USD Million)

Table 74. Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2021-2026) & (USD Million)

Table 75. Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2016-2021) & (USD Million)

Table 76. Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2021-2026) & (USD Million)

Table 77. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2016-2021) & (USD Million)

Table 78. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2021-2026) & (USD Million)

Table 79. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2016-2021) & (USD Million)

Table 80. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2021-2026) & (USD Million)

Table 81. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue by Region (2016-2021) & (USD Million)

Table 82. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue by Region (2021-2026) & (USD Million)

Table 83. South America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2016-2021) & (USD Million)

Table 84. South America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2021-2026) & (USD Million)

Table 85. South America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2016-2021) & (USD Million)

Table 86. South America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2021-2026) & (USD Million)

Table 87. South America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2016-2021) & (USD Million)

Table 88. South America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2021-2026) & (USD Million)

Table 89. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2016-2021) & (USD Million)

Table 90. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2021-2026) & (USD Million)

Table 91. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2016-2021) & (USD Million)

Table 92. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2021-2026) & (USD Million)

Table 93. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2016-2021) & (USD Million)

Table 94. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2021-2026) & (USD Million)

List of Figures

Figure 1. Prostate Cancer Nuclear Medicine Diagnostics Picture

Figure 2. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Type in 2020

Figure 3. SPECT

Figure 4. PET

Figure 5. Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Application in 2020

Figure 6. Hospitals Picture

Figure 7. Clinics Picture

Figure 8. Others Picture

Figure 9. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, (USD Million): 2020 VS 2021 VS 2026

Figure 10. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue and Forecast (2016-2026) & (USD Million)

Figure 11. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Region (2016-2026)

Figure 12. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Region in 2020

Figure 13. North America Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million) and Growth Rate (2016-2026)

Figure 14. Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million) and Growth Rate (2016-2026)

Figure 15. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million) and Growth Rate (2016-2026)

Figure 16. South America Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million) and Growth Rate (2016-2026)

Figure 17. Middle East and Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million) and Growth Rate (2016-2026)

Figure 18. Prostate Cancer Nuclear Medicine Diagnostics Market Drivers

Figure 19. Prostate Cancer Nuclear Medicine Diagnostics Market Restraints

Figure 20. Prostate Cancer Nuclear Medicine Diagnostics Market Trends

Figure 21. Blue Earth Diagnostics Recent Developments and Future Plans

Figure 22. PETNET Solutions Recent Developments and Future Plans

Figure 23. Cardinal Health Recent Developments and Future Plans

Figure 24. Lantheus Medical Imaging Recent Developments and Future Plans

Figure 25. Jubilant Pharma Recent Developments and Future Plans

Figure 26. NCM-USA Recent Developments and Future Plans

Figure 27. Progenics Pharma Recent Developments and Future Plans

Figure 28. Telix Pharma Recent Developments and Future Plans

Figure 29. ImaginAb Recent Developments and Future Plans

Figure 30. Theragnostics Recent Developments and Future Plans

Figure 31. Novartis Recent Developments and Future Plans

Figure 32. Alliance Medical Recent Developments and Future Plans

Figure 33. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Share by Players in 2020

Figure 34. Prostate Cancer Nuclear Medicine Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

Figure 35. Global Top 3 Players Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share in 2020

Figure 36. Global Top 10 Players Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share in 2020

Figure 37. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)

Figure 38. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Share by Type in 2020

Figure 39. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share Forecast by Type (2021-2026)

Figure 40. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Share by Application in 2020

Figure 41. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share Forecast by Application (2021-2026)

Figure 42. North America Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Type (2016-2026)

Figure 43. North America Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Application (2016-2026)

Figure 44. North America Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Country (2016-2026)

Figure 45. United States Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 46. Canada Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 47. Mexico Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 48. Europe Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Type (2016-2026)

Figure 49. Europe Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Application (2016-2026)

Figure 50. Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Country (2016-2026)

Figure 51. Germany Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 52. France Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 53. United Kingdom Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 54. Russia Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 55. Italy Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 56. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Type (2016-2026)

Figure 57. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Application (2016-2026)

Figure 58. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Region (2016-2026)

Figure 59. China Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 60. Japan Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 61. South Korea Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 62. India Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 63. Southeast Asia Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 64. Australia Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 65. South America Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Type (2016-2026)

Figure 66. South America Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Application (2016-2026)

Figure 67. South America Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Country (2016-2026)

Figure 68. Brazil Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 69. Argentina Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 70. Middle East and Africa Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Type (2016-2026)

Figure 71. Middle East and Africa Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Application (2016-2026)

Figure 72. Middle East and Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Country (2016-2026)

Figure 73. Turkey Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 74. Saudi Arabia Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 75. UAE Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 76. Methodology

Figure 77. Research Process and Data Source

shopping_cart License Type

Buy Now

email Quick Contact

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketsandresearch.biz